The aim of this prospective, multi-centre, exploratory research project is the establishment of a platform for in-depth tumour profiling in patients with advanced and metastatic High-Grade Adenocarcinoma (HGAC) of ovarian, tubal or peritoneal origin.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Sample Processing and Report Generation (1)
Timeframe: Through study completion, an average of 1 year
Sample Processing and Report Generation (2)
Timeframe: Through study completion, an average of 1 year
Sample Processing and Report Generation (3)
Timeframe: Through study completion, an average of 1 year
Sample Processing and Report Generation (4)
Timeframe: Through study completion, an average of 1 year
Sample Processing and Report Generation (5)
Timeframe: Through study completion, an average of 1 year
Sample Processing and Report Generation (6)
Timeframe: Through study completion, an average of 1 year
Sample Processing and Report Generation (7)
Timeframe: Through study completion, an average of 1 year
Classification of Proposed Treatment Options
Timeframe: Through study completion, an average of 1 year
Classification of Tumour Board Recommendations
Timeframe: Through study completion, an average of 1 year
Time to first subsequent treatment (TTFST)
Timeframe: Through study completion, at least 6 month of follow up
Time to first subsequent treatment (TTFST) ratio
Timeframe: Through study completion, at least 6 month of follow up
Terminations due to toxicity
Timeframe: Through study completion, at least 6 month of follow up
Survival
Timeframe: Through study completion, at least 6 month of follow up
Event free survival (EFS)
Timeframe: Through study completion, at least 6 month of follow up
Radiological tumour response
Timeframe: Through study completion, at least 6 month of follow up
Quality of Life (FAC-G7) questionnaire
Timeframe: Every 12 weeks (+/- 2 weeks) for 6 months after last tumour sampling (day 0)